{
  "claim_id": "SE-ONC-NSQNSCLC-CN-001.HARMONI_A_OS",
  "case_id": "SE-ONC-NSQNSCLC-CN-001",
  "version": "v0.1",
  "statement": "HARMONi-A final analysis reported trial-group median overall survival of 16.8 versus 14.1 months for its defined population.",
  "case_title": "China Non-Squamous NSCLC Evidence Pathway",
  "state": "SUPPORTED_FOR_TRIAL_POPULATION",
  "as_of": "2026-09-28",
  "scope": "China non-squamous NSCLC; separate stage-specific treatment contexts; detailed index cohort is EGFR-mutated locally advanced or metastatic disease after EGFR-TKI progression",
  "supports": [
    "In HARMONi-A final analysis, trial-group median OS was 16.8 vs 14.1 months, HR 0.74 (95% CI 0.58-0.95), in randomized groups of 161 each"
  ],
  "does_not_support": [
    "Randomized drug comparison only; no personal forecast or cross-modality ranking"
  ],
  "unknowns": [
    "Complete China 2026 treatment landscape",
    "Hospital-level treatment outcome datasets",
    "Updated local transplantation rules",
    "Cross-site survival linkage",
    "Pricing and publication licenses"
  ],
  "counter_evidence": [],
  "next_observable": "New regulatory indication; Updated randomized outcome; Clinically reviewed stage branch; Authorized hospital aggregate received; Correction or source retraction",
  "provenance": [
    {
      "source_ref": "cases/nsq-nsclc-china/state-v0.1.json",
      "source_role": "PRIMARY_PUBLIC_EVIDENCE_STATE"
    },
    {
      "source_ref": "cases/nsq-nsclc-china/stop-v0.1.html",
      "source_role": "HUMAN_CITATION_BOUNDARY"
    },
    {
      "source_ref": "cases/nsq-nsclc-china/publication-control-v0.1.json",
      "source_role": "PUBLICATION_AUTHORITY"
    },
    {
      "source_ref": "cases/nsq-nsclc-china/decision-memory-v0.1.json",
      "source_role": "DECISION_STRUCTURE"
    }
  ],
  "canonical_url": "https://structurevidence.org/claims/SE-ONC-NSQNSCLC-CN-001.HARMONI_A_OS.json",
  "state_url": "https://structurevidence.org/cases/nsq-nsclc-china/state-v0.1.json",
  "stop_point_url": "https://structurevidence.org/cases/nsq-nsclc-china/stop-v0.1.html",
  "method_contract": "https://structurevidence.org/method-contract.json",
  "citation_requirements": {
    "must_preserve_state": true,
    "must_preserve_as_of": true,
    "must_include_boundary_when_material": true
  },
  "aliases": [
    "non-squamous NSCLC",
    "NSCLC China",
    "lung cancer",
    "ivonescimab",
    "HARMONi-A",
    "ECMO",
    "lung transplant",
    "HARMONi-A overall survival",
    "HARMONi A OS",
    "ivonescimab overall survival"
  ],
  "keywords": [
    "harmoni-a",
    "overall",
    "survival",
    "ivonescimab",
    "16.8",
    "14.1"
  ]
}